• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Macular Edema - Pipeline Review, H2 2011 - Product Image

Macular Edema - Pipeline Review, H2 2011

  • ID: 1943740
  • October 2011
  • 158 pages
  • Global Markets Direct

Macular Edema - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Macular Edema - Pipeline Review, H2 2011', provides an overview of the Macular Edema therapeutic pipeline. This report provides information on the therapeutic development for Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Edema. 'Macular Edema - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Macular Edema.
- A review of the Macular Edema products under development by companies and universities/research institutes based on information derived READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macular Edema Overview
Therapeutics Development
An Overview of Pipeline Products for Macular Edema
Macular Edema Therapeutics under Development by Companies
Macular Edema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Macular Edema Therapeutics - Products under Development by Companies
Macular Edema Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Macular Edema Therapeutics Development
Alcon, Inc.
Abbott Laboratories
Allergan, Inc.
Sanofi-Aventis
Eli Lilly and Company
Santen Pharmaceutical Co., Ltd.
Lux Biosciences, Inc.
Novagali Pharma SA
Novartis AG
Dyax Corp.
OPKO Health, Inc.
iCo Therapeutics Inc.
Mesoblast Ltd
NicOx SA
SANWA KAGAKU KENKYUSHO CO.,LTD.
Regeneron Pharmaceuticals, Inc.
ThromboGenics NV
Molecular Partners AG
Promedior, Inc.
Akebia Therapeutics, Inc.
Inotek Pharmaceuticals Corporation
SARcode Corporation
Alimera Sciences, Inc.
Charlesson LLC.
Icon Bioscience, Inc.
Ampio Pharmaceuticals, Inc.
Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Nevanac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iCo-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DX-88 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DX-88 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ozurdex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLT-005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLT-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab - Drug Profile
Arxxant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCX 434 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Raptiva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKB-9778 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha Lipoic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alpha 2a + prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Intravitreal Triamcinolone Injections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xibrom - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Gamma- 1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diclofenac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infliximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Microplasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone + Vitrectomy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN208397 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Triamcinolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Islet Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cells For Diabetic Macular Edema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCX 422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macular Edema Therapeutics – Drug Profile Updates
Macular Edema Therapeutics - Discontinued Products
Macular Edema - Featured News
Oct 12, 2011: Alimera Sciences Highlights 36-Month FAME Study Data On ILUVIEN At American Academy of Ophthalmology 2011 Annual Meeting
Aug 17, 2011: Regeneron To Present Data From EYLEA Clinical Studies At ASRS 2011 Annual Meeting
Aug 15, 2011: iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone
Aug 03, 2011: NICE Gives Positive Recommendation To Dexamethasone For Treatment Of Common Eye Condition In Final Guidance
Jul 14, 2011: NICE Unable To Recommend Drug To Treat Diabetic Macular Edema
Jun 28, 2011: Genentech Announces Positive Results From Two Pivotal Phase III Trials Of Lucentis
Jun 06, 2011: Novartis Gains European Commission Approval For Lucentis To Treat Vision Loss Due To Macular Edema Secondary To RVO
Jun 06, 2011: NICE Recommends Allergan's OZURDEX For Treatment Of Retinal Vein Occulsion
May 13, 2011: iCo Therapeutics Engages Ora For Ophthalmic Clinical And Regulatory Guidance
May 13, 2011: Alimera Sciences Resubmits New Drug Application For ILUVIEN
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos